Results of this double-blind, phase 3 study reports on impact of lenalidomide maintenance therapy on risk of disease progression in patients with CLL who did not achieve minimal residual disease state after first-line chemoimmunotherapy.
Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.
Time to disease progression was significantly prolonged in patients with multiple myeloma who received lenalidomide therapy after ASCT.
Drug treatment rather than observation may delay disease progression and extend survival in persons with high-risk smoldering multiple myeloma, according to recent study results.
FDA-related news items of relevance from the month of June, 2013.
Imaging studies and laboratory tests were negative, but lumbar puncture revealed the cause of this patient’s unexplained neurologic symptoms.
Combining lenalidomide with low-dose rather than high-dose dexamethasone for the treatment of multiple myeloma improves survival and lowers toxicity, according to the results of a controlled trial
Multiple myeloma patients experience high response rates when treated with a drug regimen consisting of 3 drugs, according to data presented at the American Society of Hematology Annual Meeting and Exposition in New Orleans in December.
